CD8A and neoplasm: Altogether, these data indicate that although all patients in this group had low tumoral CD8 infiltrate prior to treatment, an existing inflammatory tumor microenvironment (TME) is nevertheless present in patients who are more likely to respond to nivolumab and ipilimumab.